Skip to main content

Erratum to: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

  • The original article was published in Arthritis Research & Therapy 2008 10:R124

It has been brought to our attention that Figure 2b in our recently published paper [1] contains an error. Specifically, we inadvertently entered -6.4 rather than +6.4 for the Nadaskevich paper [2] reported in Figure 2b. Recalculation of the summary estimate for diffusing lung capacity of carbon monoxide (DLCO) in this figure revealed a summary mean difference of 3.74, with 95% confidence interval (0.09 to 7.40). This effect is now statistically significant, although the overall conclusion of our meta-analysis, that cyclophosphamide treatment did not result in clinically significant improvement of pulmonary function, is unchanged by this recalculation, as the improvement remains less than the predefined criterion of 10%. The corrected figure 2b is given here as Figure 1.

Figure 1
figure1

Forest plot of the overall meta-analysis result in the randomized clinical trials. Comparison of the diffusing capacity for carbon monoxide (DLCO) at 12 months for patients with scleroderma lung disease treated with cyclophosphamide versus a control group. See Table 2 [1] for study details. RCT, randomized clinical trial; SE, standard error; CI, confidence interval; Chi2, chi-squared; df, degree of freedom; I2, I-squared; Z, Z value; Mean difference, weighted mean difference; Random, random-effects.

References

  1. 1.

    Nannini C, West CP, Erwin PJ, Matteson EL: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008, 10: R124-10.1186/ar2534.

    PubMed Central  Article  PubMed  Google Scholar 

  2. 2.

    Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25: 205-212. 10.1007/s10067-005-1157-y.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Carlotta Nannini.

Additional information

The online version of the original article can be found at 10.1186/ar2534

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nannini, C., West, C.P., Erwin, P.J. et al. Erratum to: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 11, 408 (2009). https://doi.org/10.1186/ar2679

Download citation